Literature DB >> 1592933

[11C]methionine quantitation in cancer PET studies.

S Leskinen-Kallio1, R Huovinen, K Någren, P Lehikoinen, U Ruotsalainen, M Teräs, H Joensuu.   

Abstract

Quantitation of the uptake of positron emitting tracers in cancer patients is still unsettled. A uniform method is needed for comparison of results and for collecting a data base of tumor PET studies. We have measured the tumoral uptake of [11C]methionine in 46 cancer patients using four different methods of analysis. The accumulation of [11C]methionine at 35-40 min after the injection adjusted to the injected dose and body surface area turned out to give similar results as a more complicated method where the uptake rate of [11C]methionine from the plasma to the tumor was calculated (r = 0.92, p less than 0.0001). The results suggest that in clinical [11C]methionine PET studies, 40 min emission scanning with frequent blood sampling is unnecessary. Only a single 5 min emission scan 25-40 min after the injection is required for analysis if the accumulation is adjusted to the injected dose and body surface area.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1592933     DOI: 10.1097/00004728-199205000-00023

Source DB:  PubMed          Journal:  J Comput Assist Tomogr        ISSN: 0363-8715            Impact factor:   1.826


  3 in total

1.  System a amino acid transport-targeted brain and systemic tumor PET imaging agents 2-amino-3-[(18)F]fluoro-2-methylpropanoic acid and 3-[(18)F]fluoro-2-methyl-2-(methylamino)propanoic acid.

Authors:  Weiping Yu; Jonathan McConathy; Jeffrey J Olson; Mark M Goodman
Journal:  Nucl Med Biol       Date:  2014-08-01       Impact factor: 2.408

Review 2.  Where are we with nuclear medicine in pediatrics?

Authors:  H R Nadel
Journal:  Eur J Nucl Med       Date:  1995-12

3.  Carbon-11-methionine and PET in evaluation of treatment response of breast cancer.

Authors:  R Huovinen; S Leskinen-Kallio; K Någren; P Lehikoinen; U Ruotsalainen; M Teräs
Journal:  Br J Cancer       Date:  1993-04       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.